ERAS
Erasca, Inc.
NASDAQ · Healthcare · Biotechnology · US
$13.68
+2.17%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$13.73
From 52W high−39.12%
Volume3.78M
Market cap$4.78B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$13.73
From 52W high
−39.12%
Volume
3.78M
Market cap
$4.78B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−16.0x
P/E (TTM)
—
RSI (14)
38.9
MomentumView details →
1D Return
+2.17%
YTD Return
+267.34%
SummaryUpdated Jun 1, 2026
Erasca, Inc. (NASDAQ:ERAS) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in San Diego, California. The company went public in July 2021 and focuses on developing targeted cancer therapies for patients with RAS/MAPK pathway-driven cancers. As a clinical-stage company, Erasca has no approved products or revenue yet, but maintains a robust pipeline of investigational drugs targeting various cancer types including lung cancer, colorectal cancer, acute myeloid leukemia, and brain tumors.
Similar companies
Latest newsMore news →
Erasca, Inc. announced that Chief Operating Officer Nicholas (Nik) Chetwyn will depart effective November 2, 2026.3d agoJohnson Fistel, PLLP announced it is investigating potential claims on behalf of long-term shareholders of Erasca, Inc. against certain of its officers and directors for alleged breaches of fiduciary duty.28d agoGrabar Law Office announced it is investigating whether certain officers and directors of Erasca, Inc. breached their fiduciary duties owed to the company and its shareholders.34d ago